- Latent-Y is coming to more researchers: Latent Labs will open a Research Tier on the Latent Labs Platform, giving approved researchers access to run large-scale agentic protein design campaigns directly from the browser.
- A live launch in London: on July 15, Latent Labs will host a launch event featuring a deep dive into Latent-Y and first-hand accounts from researchers with early access.
- Designs that work in the lab, from a prompt: Latent-Y is a protein design agent that designs zero-shot antibodies, peptides, and mini-binders, demonstrated, for the first time, to produce successful antibodies in the lab from natural-language prompts.
- Built with leading collaborators: the agent runs on the Latent Labs Platform alongside the Latent-X model family, with accelerated computing support from NVIDIA.
LONDON & SAN FRANCISCO, June 23, 2026 — Latent Labs today announced the upcoming launch of a Research Tier for Latent-Y, its lab-validated autonomous drug design agent, and invited the research community to a launch event in London, on July 15, 2026.
The Research Tier will give researchers accepted into the program broader access to Latent-Y on the Latent Labs Platform, with the ability to run large-scale agentic protein design campaigns directly from the browser, no specialist infrastructure or machine-learning expertise required. Registration for the launch event is open at www.luma.com/latent-y-launch.
About Latent-Y
Latent-Y is an autonomous AI agent for drug design. It is able to design zero-shot antibodies in a range of therapeutically relevant formats, peptides and mini-binder proteins. Given a design goal in plain language it handles the full workflow from prompt to lab-ready molecule: literature and database research, target analysis, epitope identification, molecular generation with Latent-X2, computational validation, delivering lab-ready binder sequences at the end. Latent-Y can run end-to-end autonomously, or pause at each stage for researcher review, keeping scientists in control of every design decision.
In published results, Latent-Y was able to design lab-confirmed antibody binders to 67% of the tested targets, with binding affinities reaching the single-digit nanomolar range, compressing weeks of expert workflow into hours.
The technology behind Latent-Y
Latent-Y runs on the Latent Labs Platform with access to Latent-X2, Latent-X1, external scientific databases, and bioinformatics tools. It can be steered in natural language and works collaboratively or autonomously, completing typical computational protein design workflows in hours rather than weeks. Delivering that speed depends on accelerated computing developed with collaborators including NVIDIA, whose BioNeMo Agent Toolkit libraries, among them cuEquivariance, have helped further accelerate Latent-Y's design pipeline since launch. Looking further ahead, Latent Labs sees fine-tunable scientific models, such as NVIDIA Nemotron open models, as a promising route to agents that learn from wet-lab results.
"We're excited to put powerful agentic systems into the hands of trusted researchers," said Simon Kohl, CEO and founder of Latent Labs. "Just as coding agents are accelerating software development, Latent-Y accelerates drug discovery, giving researchers structure-based protein design directly from a natural language prompt."
Join the launch event
The Latent-Y Research Tier launch event takes place in London, on July 15, 2026. Registration is open at www.luma.com/latent-y-launch. Broader Research Tier access details will be shared at the event and on www.latentlabs.com.
About Latent Labs
Latent Labs builds frontier generative models and autonomous agents for drug design. Its Latent-X family of models and the Latent-Y agent bring structure-based antibody, peptide, and mini-binder design to researchers through the Latent Labs Platform. Latent Labs is based in London and San Francisco. For partnerships, contact partnerships@latentlabs.com.